

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

Carlos GARCIA-ECHEVERRIA et al.

Examiner: RAO, Deepak R.

APPLICATION NO: 10/568,367

FILED: 18 August 2006

FOR: 2,4-Pyrimidinediamines Useful in the Treatment of Neoplastic  
Diseases, Inflammatory and Immune System Disorders

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**SUBMISSION OF SEQUENCE LISTING**  
**INCLUDING STATEMENT OF VERIFICATION**

Sir:

Applicants hereby provide a Computer Readable Form (CRF) of the Sequence Listing as well as the Paper Copy thereof. The undersigned states that the Paper Copy and the Computer Readable Form (CRF), submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same, and include no new matter.

Novartis Institutes for BioMedical Research, Inc.  
220 Massachusetts Avenue  
Cambridge, MA 02139

(617) 871-7347

Date: 30 July 2009

Respectfully submitted,



Mark E. Baron  
Attorney for Applicant  
Reg. No. 46,150